Two drugs are better than one-modeling drug combinations in cancer therapy

Science Translational Medicine

Volumn 5, Issue 194, 2013, Pages

  Callahan, Margaret K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DABRAFENIB; ERLOTINIB; GEFITINIB; IMATINIB; VEMURAFENIB;

CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CROSS RESISTANCE; DISEASE CONTROL; EDITORIAL; GENE MUTATION; HUMAN; IMMUNE SYSTEM; IMMUNOTHERAPY; LUNG CANCER; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; MELANOMA; PRIORITY JOURNAL;

EID: 84880519018     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006923     Document Type: Editorial

References (1)

1. I. Bozic et al., Evolutionary dynamics of cancer in response to targeted combination therapy. eLife 2, e00747 (2013).